Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop fordry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

Health Care

Health Diagnostics

Therapeutics

Cambium Medical Technologies

Terence A. Walts

Tina W. McKeon

Clayton W. Coley

Neera Jagirdar

Michael Broughton

Dennis E. Hannigan

John D. Roback

Edmund K. Waller

The Leadership Team at Cambium Medical Technologies is responsible for setting the strategic direction of the company, overseeing the development and commercialization of regenerative therapies, and ensuring regulatory compliance and financial stability. They guide the organization's vision, manage key partnerships, and drive the progress of innovative treatments like Elate Ocular through clinical and regulatory pathways.

Leadership Team

Medical Advisory Team

Legal and Regulatory Affairs Team

Leadership Team

About

Team members

Other teams at Cambium Medical Technologies

Medical Advisory Team

Legal and Regulatory Affairs Team